Matthew R. Allen, PhD
Associate Professor of Anatomy & Cell Biology
The laboratory led by Matthew R. Allen, PhD studies the tissue-level mechanisms responsible for musculoskeletal integrity in health and disease by utilizing numerous in vivo model systems that help investigators understand how disease and pharmaceutical intervention influence bone structure, cellular activity, tissue-level properties (such as mineralization, microdamage, collagen, hydration), and biomechanical properties.
The laboratory studies a range of diseases/conditions, including osteoporosis, chronic kidney disease, and disuse using techniques that include imaging (CT, DXA, X-ray), histology (static and dynamic histomorphometry, microdamage), and mechanical testing (bending, compression, fatigue loading).
Titles & Appointments
- Adjunct Associate Professor of Medicine
- Adjunct Associate Professor of Orthopaedic Surgery
Combination treatment to enhance bone strength
NIH/NIAMS-funded project: Pharmaceutical agents used to treat osteoporosis significantly reduce fracture risk via different mechanisms that ultimately enhance either structural or material biomechanical properties. This proposal will determine if FDA approved anti- osteoporotic drugs can be used in combination to enhance bone mechanical properties more than treatment with either drug alone.
Treating skeletal complications of chronic kidney disease
NIH/NIAMS-funded project: One in ten Americans suffers from chronic kidney disease (CKD). Individuals with end-stage CKD have a 17-fold higher risk of skeletal fracture than the normal population and of CKD patients that sustain a hip fracture over 60% die within a year (compared to 20% in the normal population). Our work in this field is focused on gaining a greater understanding of the underlying skeletal schanges associated with CKD and finding a viable treatment for these changes. This work is done in collaboration with Dr. Sharon Moe, a clinical nephrologist.
Novel approaches to altering bone mechanical properties
In conjuction with Dr. David Burr our laboratory has shown that raloxifene, a selective estrogen receptor modulator, can alter bone mechanical properties through non-cellular mechanisms. Current work is aimed at undersanding the mechanisms underlying these benefical modifications.